In 2012, the federal Centers for Medicare and Medicaid Services (CMS) launched the National Partnership to Improve Dementia Care to reduce the use of dangerous antipsychotic (AP) drugs in nursing homes. This report, “A Decade of Drugging,” examines how dementia care has – and hasn’t – changed since the launch of the Partnership and finds that a once-promising campaign has sputtered and fallen short of its goals to curb AP drug use.
This page contains a PDF of the report along with supplementary materials including comprehensive AP drugging datasets, an interactive Tableau dashboard illustrating state and national AP drugging trends, a list of commonly prescribed AP drugs (generic and brand names), and dementia care resources to support resident-centered advocacy.
Antipsychotic Drugs by the Numbers
Antipsychotic Drugging & Schizophrenia Rates (2012-2021)
|Year (Q2)||Risk-Adjusted||Non-Risk-Adjusted||Percent Excluded||Schizophrenia Rate|
Sources: MDS 3.0 Frequency Reports & CMS National Partnership
CMS’s risk-adjusted AP drugging metric excludes residents with a diagnosis of schizophrenia, Huntington’s Disease, or Tourette’s Syndrome. Researchers have found that the modest declines in AP drugging rates stem from significant increases in false schizophrenia diagnoses. Since the start of the Partnership, the share of residents receiving APs but excluded by the risk-adjusted metric has nearly tripled, largely due to increases in false schizophrenia diagnoses.